Evidence map›Paper›PMID 38835749›Full record

ArticleAllergologie select2024

"Delabeling" by direct provocation testing in children and adolescents with a suspected history of a delayed reaction to β-lactam antibiotics: Consensus paper of Gesellschaft für pädiatrische Allergologie und Umweltmedizin (GPAU), Deutsche Gesellschaft für Allergologie und klinische Immunologie (DGAKI), and Ärzteverband deutscher Allergologen (ÄDA).

Irena Neustädter, Sophie Blatt, Gerda Wurpts, Heinrich Dickel, Christian Walter, Werner Aberer, Sebastian Bode, Timo Buhl, Sunhild Gernert, Susanne Harner and 14 more

Abstract read
In one paragraph

Article in Allergologie select, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Irena NeustädterPediatric and Adolescent Medicine, Diakoneo Klinik Hallerwiese-Cnopfsche Kinderklinik, Nuremberg.
Sophie BlattPediatric and Adolescent Medicine, Diakoneo Klinik Hallerwiese-Cnopfsche Kinderklinik, Nuremberg.
Gerda WurptsClinic for Dermatology and Allergology, Aachen Comprehensive Allergy Center (ACAC), University Hospital of RWTH Aachen University, Aachen.
Heinrich DickelClinic for Dermatology, Venereology and Allergology, St. Josef Hospital, University Hospital of the Ruhr University Bochum, Bochum.
Christian WalterPractice for Pediatric and Adolescent Medicine, Allergology, Bad Homburg, Germany.
Werner AbererDepartment of Dermatology and Venereology, Medical University of Graz, Austria.
Sebastian BodeUniversity Clinic for Children and Adolescents, Ulm.
Timo BuhlDepartment of Dermatology, Venereology and Allergology, University Medical Center Göttingen.
Sunhild GernertDepartment of Pediatrics, St. Marien Hospital, GFO Clinics, Bonn.
Susanne HarnerClinic and Polyclinic for Pediatrics and Adolescent Medicine, University of Regensburg, Regensburg.
Guido HeineDepartment of Dermatology, Venereology and Allergology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel.
Sebastian KerzelClinic and Polyclinic for Pediatrics and Adolescent Medicine, University of Regensburg, Regensburg.
Meike KöhlerAsthma and Allergy Outpatient Clinic, Dr. von Hauner Children's Hospital, LMU University Hospital, Munich.
Lars LangeDepartment of Pediatrics, St. Marien Hospital, GFO Clinics, Bonn.
Joachim ListUniversity of Freiburg, Center for Pediatric and Adolescent Medicine, Freiburg.
Hans F MerkClinic and Polyclinic for Dermatology and Allergology at Biederstein, Technical University of Munich, Munich.
Thomas NüßleinClinic for Pediatrics and Adolescent Medicine, Gemeinschaftsklinikum Mittelrhein, Koblenz.
Hagen OttChildren's and Youth Hospital Auf der Bult, Hanover.
Franziska SattlerAsthma and Allergy Outpatient Clinic, Dr. von Hauner Children's Hospital, LMU University Hospital, Munich.
Antje SchusterClinic for General Pediatrics, Neonatology and Pediatric Cardiology, University Hospital Düsseldorf, Düsseldorf.
Helen StraubePrincess Margaret Children's Hospital, Darmstadt.
Bettina WediHannover Medical School, Clinic for Dermatology, Allergology and Venereology, Hanover, and.
Torsten ZuberbierAllergology and Immunology, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Knut BrockowClinic and Polyclinic for Dermatology and Allergology at Biederstein, Technical University of Munich, Munich.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproximately 10% of European children are classified as allergic to drugs. In the majority of these children, no allergy to β-lactam antibiotics (BLA) can be found. In most cases, the exanthema is caused by the infection. MATERIALS AND

methodsThe objective of this paper is to describe the causes and consequences of a misdiagnosis of drug allergy. We propose a method for establishing a correct diagnosis in the case of a history of a delayed reaction during treatment with a BLA. For this purpose, a proposal was discussed via e-mail communication, and consensus was reached among the members of the drug allergy working groups of the participating medical societies.

resultsThe suspicion of a BLA allergy based on the medical history alone can have a negative impact on future antibiotic treatment. Exanthema associated with febrile infections not related to drug administration is a frequent finding in children. This makes it all the more important to be able to recommend a standardized procedure for clarification in children and adolescents with suspected hypersensitivity reactions. The medical history should be the basis on which to diagnose either a drug allergy or another possible differential diagnosis. A mild maculopapular exanthema (MPE) can be an expression of a drug allergy or a nonspecific viral exanthema. Uncomplicated MPE is not associated with significant systemic involvement, and there is no involvement of the mucous membranes or cutaneous blistering. Only a small number of children with uncomplicated MPE show positive skin tests and only ~ 7 - 16% of suspected BLA diagnoses can be confirmed by provocation tests. Thus, in children with uncomplicated MPE, drug provocation can be performed in an outpatient setting even without prior skin testing. This paper presents a 3-day outpatient direct provocation scheme for BLA delabeling in children with uncomplicated MPE.

conclusionMany children and adolescents are unnecessarily denied treatment with BLA after an uncomplicated MPE while being treated with a BLA.

Indexed as

allergybenign rashdirect drug provocation testingβ-lactams

Identifiers

PMID38835749
PMCPMC11149545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.